KEY POINTS
- This case report from St Luke's Radiation Oncology Network, Ireland, describes a 53-year-old man with recurrent nonseminomatous germ cell tumor (NSGCT) and oligoprogressive retrocrural lymphadenopathy after multiple prior treatments. Initial management in 2002 included left orchidectomy, retroperitoneal lymph node dissection demonstrating differentiated teratoma, and BEP chemotherapy. Following supraclavicular recurrence in 2022, additional platinum-based treatment was complicated by severe refractory seizures requiring intensive care, making further chemotherapy unsuitable. Subsequent palliative RT to the neck (20 Gy in five fractions) produced no response, and neck dissection in June 2024 demonstrated an 85-mm mature cystic teratoma.
- During surveillance, serum alpha-fetoprotein (AFP) increased from 30.4 to 49.2 ng/mL. PET/CT in March 2025 demonstrated a solitary 2.9 × 1.5 cm FDG-avid right retrocrural lymph node (SUVmax 15.9) without evidence of progression elsewhere. Multidisciplinary assessment considered the lesion unresectable because of proximity to major vascular and neural structures, while further chemotherapy was contraindicated by previous life-threatening neurological toxicity. SABR was therefore selected as a metastasis-directed approach intended to provide durable local control.
- SABR delivered 42 Gy in three fractions on alternate days using VMAT with inverse planning. Four-dimensional CT was used to assess respiratory motion, generating an internal target volume expanded by 5 mm to produce the PTV. Reported planning metrics included PTV D95 of 96% of prescription, D99 of 91.98%, and Dmax of 116.12%, with treatment delivered using daily CBCT image guidance. There was no overlap with the patient's previously irradiated neck volume.
- All reported OAR constraints were achieved, although selected serial-structure doses approached institutional limits. The maximum dose to 0.1 cm³ of the great vessels was 44.22 Gy, compared with a 45-Gy constraint, while spinal canal D0.1cc was 17.39 Gy, compared with an 18-Gy limit. Duodenal D0.1cc was 13.97 Gy against a 22-Gy constraint, while corresponding small-bowel and large-bowel near-maximum doses were 11.51 and 14.67 Gy, respectively. The highly conformal treatment geometry allowed delivery of an ablative schedule adjacent to several critical structures.
- Radiological response was sustained through 15 months of follow-up. The retrocrural lesion decreased from approximately 2.9 × 1.3 cm before treatment to 1.2 × 0.9 cm at four months, measuring approximately 1 cm at seven months. CT imaging at 12 and 15 months showed no residual visible disease. AFP decreased to 3.7 ng/mL at four months, 2.8 ng/mL at seven months, and remained below 2.7 ng/mL at 12 and 15 months, providing concordant biochemical evidence of disease response.
- Treatment was completed without interruption or significant acute gastrointestinal toxicity. The only reported adverse effect was grade 1 fatigue, which resolved within one month. The absence of severe acute toxicity is encouraging given the lesion's proximity to the aorta, bowel, and spinal canal, but the case provides no reliable estimate of uncommon or delayed complications, particularly because follow-up was limited to 15 months.
- The evidence remains limited to an individual clinical observation. No pathological confirmation of the retrocrural lesion was reported, and its precise histological composition was therefore uncertain. Although the radiological response and normalization of AFP strongly support treatment activity in this patient, they cannot establish that SABR is consistently effective in NSGCT or identify an optimal ablative prescription. The findings are most relevant to highly selected situations in which standard chemotherapy and surgery are not feasible.
CLINICAL TAKEAWAY
SABR may provide a local treatment option for selected patients with oligoprogressive nonseminomatous germ cell tumors when further systemic therapy or surgery is not feasible, as illustrated by sustained radiological and biochemical response after 42 Gy in three fractions. However, this single case cannot establish durable efficacy, optimal fractionation, or comparative safety, and multidisciplinary selection remains essential.